Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Rheumatology | Musculoskeletal | Immunology | Family Medicine
Disease Category: Rheumatoid Arthritis
Location: United States, MD
Phase 3 Randomized, Double-Blind Study of the Efficacy and Safety of 2 Doses of JAK-3, Compared to Methotrexate Naive patients with Rheumatoid Arthritis
Do you have Rheumatoid arthritis? You may qualify to participate in a clinical research study.
JAK-3 inhibitors represent the first oral class of medication to have a demonstrable effect on a targeted component of the immune system. Seropositive rheumatoid arthritis patients are needed for this study. This double-blinded placebo controlled phase III trial is for a 2 year period, but does not limit patients to prior drug failures.
CW ID: 169936
Date Last Changed:
July 23, 2013
The Center for Rheumatology and Bone Research2730 University Blvd West, Suite 306Wheaton, MD 20902Phone: 301 942-6610Fax: 301 942-7833
The Center for Rheumatology and Bone Research
If you would like to learn more about participating in this research study, please email the trial contact using the form below.
We value your privacy and your information will only be used by the research center to contact
you regarding this study.
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.
Copyright © 1995-2017 CenterWatch.